Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCRx for Tolerance in Living Kidney Allograft Recipients
NCT00497926Phase 2Terminated
- Sponsor
- Talaris Therapeutics
- Start
- Mar 2008
- Primary completion
- Mar 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FCR001 in kidney failure (ESRD), sponsored by Talaris Therapeutics. Primary endpoint: Enriched Hematopoietic Stem Cell Engraftment at 3 years. Started Mar 2008; status: terminated.
02
Drugs
FCR001
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT00497926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00497926.